JustineMarieKentMD

Psychiatry • Fort Lee, NJ

Senior Director, Janssen R&D, Johnson & Johnson

Join to view full profile

Dr. Kent is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Kent's full profile

Already have an account?

Office
1 Bridge Plaza N
Sunovion Pharmaceuticals, Inc.
Fort Lee, NJ 07024
Phone+1 508-787-4534

Education & Training

New York Presbyterian Hospital (Columbia Campus)/New York State Psychiatric InstituteResidency, Psychiatry, 1991 - 1995
New York University School of MedicineClass of 1991

Certifications & Licensure

NJ State Medical License 2000 - 2021

Publications & Presentations

PubMed

12 citations
A Randomized, Double-blind, Placebo-controlled Proof-of-Concept Trial to Evaluate the Efficacy and Safety of Non-racemic Amisulpride (SEP-4199) for the Treatment of Bi...
Antony Loebel, Kenneth S. Koblan, Joyce Tsai, Ling Deng, Maurizio Fava
Journal of Affective Disorders. 2022-01-01
17 citations
Efficacy and safety of dasotraline in adults with binge-eating disorder: a randomized, placebo-controlled, fixed-dose clinical trial.
Carlos M. Grilo, Susan L. McElroy, James I. Hudson, Joyce Tsai, Bradford Navia
CNS Spectrums. 2021-10-01
4 citations
Dasotraline in adults with attention deficit hyperactivity disorder: a placebo-controlled, fixed-dose trial.
Lenard A. Adler, Robert Goldman, Seth C. Hopkins, Kenneth S. Koblan, Justine Kent
International Clinical Psychopharmacology. 2021-03-12

Press Mentions

Sunovion Announces Results from Its Open-Label Extension Study of SEP-363856 in SchizophreniaDecember 12th, 2019
Sunovion and PsychoGenics Initiate DIAMOND Phase 3 Clinical Studies for SEP-363856 in the Treatment of Adults and Adolescents with SchizophreniaSeptember 27th, 2019